跳转至内容
Merck
CN

676490

VEGFR2D1-7, Human, Recombinant, S. frugiperda

别名:

Vascular Endothelial Growth Factor Receptor 2 D1-7, Soluble KDR/Flk-1

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.77
UNSPSC Code:
12352202
Assay:
≥90% (SDS-PAGE)
Form:
lyophilized
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥90% (SDS-PAGE)

Quality Level

form

lyophilized

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

solubility

aqueous buffer: ≥100 μg/mL, water: ≥100 μg/mL

shipped in

wet ice

storage temp.

−70°C

General description

Recombinant, human VEGFR-2 consisting of all 7 immunoglobulin-like extracellular domains, but lacking the single transmembrane region and the intracellular split tyrosine kinase domain expressed in S. frugiperda insect cells. Contains all of the domains necessary for high affinity binding to VEGF. VEGFR-2 has a lower affinity for VEGF165 than VEGFR-1. However, VEGFR-2 has a higher signaling activity and is reported to mediate almost all observed endothelial cell responses to VEGF, including the increased microvascular permeability and endothelial cell proliferation. VEGFR-2 requires heparin for binding VEGF165.

Biochem/physiol Actions

Measured by the ability to inhibit VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells

Physical form

Lyophilized from 100 mM NaCl, 25 mM MES, pH 5.5.

Preparation Note

Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C. Avoid freeze/thaw cycles of solutions.

Other Notes

Robinson, C.J., and Stringer, S.E. 2001 J. Cell Sci.114, 853.
Roeckl, W., et al. 1998. Exp. Cell Res.241, 161.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品

此项目有


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Melis Denizci Öncü et al.
Biotechnology and applied biochemistry, 69(5), 2122-2137 (2021-10-26)
Development of monoclonal antibody therapeutics against vascular endothelial growth factor receptor 2 (VEGFR-2) protein, which is the main regulator in angiogenesis, has been a major challenge for years. In the current study, we engineer an inclusion body forming single-chain variable

全球贸易项目编号

货号GTIN
676490-50UG04055977183665

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持